족저근막염 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Plantar Fasciitis Treatment Market (Type: Medication Therapy, Orthotics, Shockwave Therapy, Surgery, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

US $ 5,795 ￦ 8,366,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 12,698,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 17,029,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

족저근막염 치료 시장 - 조사 범위

TMR의 세계 족저근막염 치료 시장에 대한 조사 보고서는 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 추세와 기회를 조사하고 2023년을 기준 연도로, 2031년을 예측 연도로 삼고 있다, 2017년부터 2031년까지 세계 족저근막염 치료 시장의 수익과 예측을 제공합니다. 또한 2023년부터 2031년까지 세계 족저근막염 치료 시장의 복합 연간 성장률(CAGR%)도 제공합니다.

이 보고서는 광범위한 조사 조사를 통해 작성되었으며, KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 주요 기업의 제품 자료, 연례 보고서, 보도 자료 및 관련 문서를 검토하여 족저근막염 치료 시장을 이해하고자 2차 조사를 실시했습니다. 참고하였습니다.

시장 현황
2022년 시장 가치	7억 7,830만 달러
2031년 시장 가치	11억 달러
CAGR	4.3%

이 보고서는 세계 족저근막염 치료 시장의 경쟁 환경을 조사했습니다. 세계 족저근막염 치료 시장에서 사업을 운영하는 주요 기업이 확인되었으며, 각 기업은 다양한 속성으로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 시장 개발, SWOT는 이 보고서에 소개된 세계 족저근막염 치료 시장 기업의 속성입니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 서론
• 시장 개요
• 시장 역학
• 세계 시장 분석과 예측, 2017-2031년

제5장 주요 인사이트

• 파이프라인 분석
• 주요 제품/브랜드 분석
• 주요 M&A
• COVID-19 팬데믹의 산업에 대한 영향

제6장 세계 시장 분석과 예측 : 유형별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출 예측 : 유형별, 2017년-2031년
  • 약물 요법
    • 경구
    • 비경구
  • 충격파 치료
    • 체외 충격파 치료(ESWT)
    • 체외 공기압 충격파 치료(IPST)
  • 외과 수술
  • 장비
  • 기타
• 시장의 매력 분석 : 유형별

제7장 세계 시장 분석과 예측 : 최종사용자별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 매출 예측 : 최종사용자별, 2017년-2031년
  • 병원
  • 클리닉
  • 기타
• 시장의 매력 분석 : 최종사용자별

제8장 세계 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 매출 예측 : 지역별, 2017년-2031년
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역별

제9장 북미 시장 분석과 예측

제10장 유럽 시장 분석과 예측

제11장 아시아태평양 시장 분석과 예측

제12장 라틴아메리카 시장 분석과 예측

제13장 중동 및 아프리카 시장 분석과 예측

제14장 경쟁 구도

• 시장 경쟁 매트릭스(Tier별, 기업 규모별)
• 시장 점유율 분석 : 기업별(2022년)
• 기업 개요
  • Hanger, Inc.
  • Bayer Group(Dr. Scholl's)
  • A. Algeo Limited
  • Bauerfeind AG
  • Superfeet Worldwide, Inc.
  • Ottobock SE & Co. KGaA(Ottobock Holding)
  • Pfizer, Inc.
  • Sanofi
  • GlaxoSmithKline plc

LSH

영문 목차

영문목차

Plantar Fasciitis Treatment Market - Scope of Report

TMR's report on the global plantar fasciitis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global plantar fasciitis treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global plantar fasciitis treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the plantar fasciitis treatment market.

Market Snapshot
Market Value in 2022	US$ 778.3 Mn
Market Value in 2031	US$ 1.1 Bn
CAGR	4.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global plantar fasciitis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global plantar fasciitis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global plantar fasciitis treatment market.

The report delves into the competitive landscape of the global plantar fasciitis treatment market. Key players operating in the global plantar fasciitis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global plantar fasciitis treatment market profiled in this report.

Key Questions Answered in Global plantar fasciitis treatment Market Report:

• What is the sales/revenue generated by plantar fasciitis treatment across all regions during the forecast period?
• What are the opportunities in the global plantar fasciitis treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Plantar Fasciitis Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global plantar fasciitis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global plantar fasciitis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global plantar fasciitis treatment market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Plantar Fasciitis Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Plantar Fasciitis Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Type, 2017-2031
  • 6.3.1. Medication Therapy
    • 6.3.1.1. Oral
    • 6.3.1.2. Parenteral
  • 6.3.2. Shockwave Therapy
    • 6.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
    • 6.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
  • 6.3.3. Surgery
  • 6.3.4. Orthotics
  • 6.3.5. Others
• 6.4. Market Attractiveness Analysis, by Type

7. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by End-user

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by End-user, 2017-2031
  • 7.3.1. Hospitals
  • 7.3.2. Clinics
  • 7.3.3. Others
• 7.4. Market Attractiveness Analysis, by End-user

8. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region, 2017-2031
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness Analysis, by Region

9. North America Plantar Fasciitis Treatment Market Analysis and Forecast

• 9.1. Introduction
• 9.2. Key Findings
• 9.3. Market Value Forecast, by Type, 2017-2031
  • 9.3.1. Medication Therapy
    • 9.3.1.1. Oral
    • 9.3.1.2. Parenteral
  • 9.3.2. Shockwave Therapy
    • 9.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
    • 9.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
  • 9.3.3. Surgery
  • 9.3.4. Orthotics
  • 9.3.5. Others
• 9.4. Market Value Forecast, by End-user, 2017-2031
  • 9.4.1. Hospitals
  • 9.4.2. Clinics
  • 9.4.3. Others
• 9.5. Market Value Forecast, by Country, 2017-2031
  • 9.5.1. U.S.
  • 9.5.2. Canada
• 9.6. Market Attractiveness Analysis
  • 9.6.1. By Type
  • 9.6.2. By End-user
  • 9.6.3. By Country

10. Europe Plantar Fasciitis Treatment Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Type, 2017-2031
  • 10.3.1. Medication Therapy
    • 10.3.1.1. Oral
    • 10.3.1.2. Parenteral
  • 10.3.2. Shockwave Therapy
    • 10.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
    • 10.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
  • 10.3.3. Surgery
  • 10.3.4. Orthotics
  • 10.3.5. Others
• 10.4. Market Value Forecast, by End-user, 2017-2031
  • 10.4.1. Hospitals
  • 10.4.2. Clinics
  • 10.4.3. Others
• 10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 10.5.1. Germany
  • 10.5.2. U.K.
  • 10.5.3. France
  • 10.5.4. Italy
  • 10.5.5. Spain
  • 10.5.6. Rest of Europe
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Type
  • 10.6.2. By End-user
  • 10.6.3. By Country/Sub-region

11. Asia Pacific Plantar Fasciitis Treatment Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Type, 2017-2031
  • 11.3.1. Medication Therapy
    • 11.3.1.1. Oral
    • 11.3.1.2. Parenteral
  • 11.3.2. Shockwave Therapy
    • 11.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
    • 11.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
  • 11.3.3. Surgery
  • 11.3.4. Orthotics
  • 11.3.5. Others
• 11.4. Market Value Forecast, by End-user, 2017-2031
  • 11.4.1. Hospitals
  • 11.4.2. Clinics
  • 11.4.3. Others
• 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.5.1. China
  • 11.5.2. Japan
  • 11.5.3. India
  • 11.5.4. Australia & New Zealand
  • 11.5.5. Rest of Asia Pacific
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Type
  • 11.6.2. By End-user
  • 11.6.3. By Country/Sub-region

12. Latin America Plantar Fasciitis Treatment Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Type, 2017-2031
  • 12.3.1. Medication Therapy
    • 12.3.1.1. Oral
    • 12.3.1.2. Parenteral
  • 12.3.2. Shockwave Therapy
    • 12.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
    • 12.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
  • 12.3.3. Surgery
  • 12.3.4. Orthotics
  • 12.3.5. Others
• 12.4. Market Value Forecast, by End-user, 2017-2031
  • 12.4.1. Hospitals
  • 12.4.2. Clinics
  • 12.4.3. Others
• 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Type
  • 12.6.2. By End-user
  • 12.6.3. By Country/Sub-region

13. Middle East & Africa Plantar Fasciitis Treatment Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Type, 2017-2031
  • 13.3.1. Medication Therapy
    • 13.3.1.1. Oral
    • 13.3.1.2. Parenteral
  • 13.3.2. Shockwave Therapy
    • 13.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
    • 13.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
  • 13.3.3. Surgery
  • 13.3.4. Orthotics
  • 13.3.5. Others
• 13.4. Market Value Forecast, by End-user, 2017-2031
  • 13.4.1. Hospitals
  • 13.4.2. Clinics
  • 13.4.3. Others
• 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.5.1. GCC Countries
  • 13.5.2. South Africa
  • 13.5.3. Rest of Middle East & Africa
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Type
  • 13.6.2. By End-user
  • 13.6.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 14.2. Market Share Analysis, by Company (2022)
• 14.3. Company Profiles
  • 14.3.1. Hanger, Inc.
    • 14.3.1.1. Company Overview
    • 14.3.1.2. Product Portfolio
    • 14.3.1.3. SWOT Analysis
    • 14.3.1.4. Financial Overview
    • 14.3.1.5. Strategic Overview
  • 14.3.2. Bayer Group (Dr. Scholl's)
    • 14.3.2.1. Company Overview
    • 14.3.2.2. Product Portfolio
    • 14.3.2.3. SWOT Analysis
    • 14.3.2.4. Financial Overview
    • 14.3.2.5. Strategic Overview
  • 14.3.3. A. Algeo Limited
    • 14.3.3.1. Company Overview
    • 14.3.3.2. Product Portfolio
    • 14.3.3.3. SWOT Analysis
    • 14.3.3.4. Financial Overview
    • 14.3.3.5. Strategic Overview
  • 14.3.4. Bauerfeind AG
    • 14.3.4.1. Company Overview
    • 14.3.4.2. Product Portfolio
    • 14.3.4.3. SWOT Analysis
    • 14.3.4.4. Financial Overview
    • 14.3.4.5. Strategic Overview
  • 14.3.5. Superfeet Worldwide, Inc.
    • 14.3.5.1. Company Overview
    • 14.3.5.2. Product Portfolio
    • 14.3.5.3. SWOT Analysis
    • 14.3.5.4. Financial Overview
    • 14.3.5.5. Strategic Overview
  • 14.3.6. Ottobock SE & Co. KGaA (Ottobock Holding)
    • 14.3.6.1. Company Overview
    • 14.3.6.2. Product Portfolio
    • 14.3.6.3. SWOT Analysis
    • 14.3.6.4. Financial Overview
    • 14.3.6.5. Strategic Overview
  • 14.3.7. Pfizer, Inc.
    • 14.3.7.1. Company Overview
    • 14.3.7.2. Product Portfolio
    • 14.3.7.3. SWOT Analysis
    • 14.3.7.4. Financial Overview
    • 14.3.7.5. Strategic Overview
  • 14.3.8. Sanofi
    • 14.3.8.1. Company Overview
    • 14.3.8.2. Product Portfolio
    • 14.3.8.3. SWOT Analysis
    • 14.3.8.4. Financial Overview
    • 14.3.8.5. Strategic Overview
  • 14.3.9. GlaxoSmithKline plc
    • 14.3.9.1. Company Overview
    • 14.3.9.2. Product Portfolio
    • 14.3.9.3. SWOT Analysis
    • 14.3.9.4. Financial Overview
    • 14.3.9.5. Strategic Overview

관련자료